Show Summary Details
Page of

Denosumab 

Denosumab
Chapter:
Denosumab
Author(s):

Celia L. Gregson

DOI:
10.1093/med/9780198713340.003.0011
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 September 2020

Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor κB ligand (RANKL) and acts as an anti-resorptive agent by inhibiting osteoclast function.

Denosumab (60 mg) is given by 6-monthly subcutaneous injection to treat post-menopausal osteoporosis.

The randomized controlled trial FREEDOM showed denosumab significantly reduced vertebral, non-vertebral, and hip fractures over 3 years in post-menopausal women.

Denosumab has been well tolerated in trials to date but carries a small increased risk of infections, e.g. cellulitis.

In renal failure, denosumab does not need a dose adjustment; however, it may increase the risk of hypocalcaemia.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.